Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
You’ve seen the headlines. Now let’s break them open. Sasha-Ann Simons connects you with the people behind the stories: experts, neighbors and newsmakers who shape the city we share. It’s news, ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Apr. 7, 2026 A gene called KLF5 may be a key force behind the spread of pancreatic cancer—but not in the way scientists expected. Rather than mutating DNA, it rewires how genes are turned on and off, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results